243 related articles for article (PubMed ID: 27257245)
1. DNA REPAIR. Drugging DNA repair.
Jackson SP; Helleday T
Science; 2016 Jun; 352(6290):1178-9. PubMed ID: 27257245
[No Abstract] [Full Text] [Related]
2. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
3. DNA damage checkpoint kinases in cancer.
Smith HL; Southgate H; Tweddle DA; Curtin NJ
Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
[TBL] [Abstract][Full Text] [Related]
4. Targeting the replication stress response in cancer.
Forment JV; O'Connor MJ
Pharmacol Ther; 2018 Aug; 188():155-167. PubMed ID: 29580942
[TBL] [Abstract][Full Text] [Related]
5. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
6. PARPi focus the spotlight on replication fork protection in cancer.
Schlacher K
Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways.
Keimling M; Volcic M; Csernok A; Wieland B; Dörk T; Wiesmüller L
FASEB J; 2011 Nov; 25(11):3849-60. PubMed ID: 21778326
[TBL] [Abstract][Full Text] [Related]
8. Targeting WEE1 Kinase in Cancer.
Matheson CJ; Backos DS; Reigan P
Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
[TBL] [Abstract][Full Text] [Related]
10. The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors.
van Bijsterveldt L; Durley SC; Maughan TS; Humphrey TC
Clin Cancer Res; 2021 Feb; 27(4):937-962. PubMed ID: 33257428
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
Leijen S; Beijnen JH; Schellens JH
Curr Clin Pharmacol; 2010 Aug; 5(3):186-91. PubMed ID: 20406171
[TBL] [Abstract][Full Text] [Related]
12. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
13. Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Bowden NA; Ashton KA; Vilain RE; Avery-Kiejda KA; Davey RJ; Murray HC; Budden T; Braye SG; Zhang XD; Hersey P; Scott RJ
PLoS One; 2013; 8(8):e70424. PubMed ID: 23940574
[TBL] [Abstract][Full Text] [Related]
14. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
15. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
16. Chemical strategies for development of ATR inhibitors.
Llona-Minguez S; Höglund A; Jacques SA; Koolmeister T; Helleday T
Expert Rev Mol Med; 2014 May; 16():e10. PubMed ID: 24810715
[TBL] [Abstract][Full Text] [Related]
17. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
18. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
19. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
[TBL] [Abstract][Full Text] [Related]
20. The development of ataxia telangiectasia mutated kinase inhibitors.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]